Axonics (AXNX)
(Delayed Data from NSDQ)
$70.24 USD
-0.04 (-0.06%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $70.24 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$70.24 USD
-0.04 (-0.06%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $70.24 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth A Momentum C VGM
Zacks News
Axonics Shares Fall Despite Australia's Approval for R20 SNM Device
by Zacks Equity Research
AXNX's R20 rechargeable SNM system, offering long-lasting treatment for bladder and bowel dysfunction, gains approval in Australia.
Axonics Stock Rises on Favorable Verdict in Patent Case With Medtronic
by Zacks Equity Research
AXNX stock continues to gain following a favorable court ruling last week in a patent litigation with Medtronic.
Axonics Modulation Technologies (AXNX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 62.50% and 1.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx (LUNG) delivered earnings and revenue surprises of 4.88% and 2.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy
by Zacks Equity Research
Axonics (AXNX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System
by Zacks Equity Research
Axonics' (AXNX) fourth-generation rechargeable Sacral Neuromodulation system will reduce the frequency of patient recharges significantly. The new form factor ensures ease of use.
Axonics Modulation Technologies (AXNX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 116.67% and 0.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
American Well Corporation (AMWL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
American Well Corporation (AMWL) delivered earnings and revenue surprises of 10.53% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include Axonics, Enerpac Tool Group, Cardinal Health and Acuity Brands
by Zacks Equity Research
Axonics, Enerpac Tool Group, Cardinal Health and Acuity Brands are part of the Zacks Screen of the Week article.
4 Stocks Backed by High Efficiency to Enrich Your Portfolio
by Santanu Roy
Invest in companies like Axonics (AXNX), Enerpac Tool Group (EPAC), Cardinal Health (CAH) and Acuity Brands (AYI) due to higher efficiency levels.
Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
Buy These 4 Low-Beta Stocks to Counter Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Virco Mfg (VIRC), Galapagos NV (GLPG), Axonics (AXNX) and Stride (LRN) are well-poised to gain.
Zacks.com featured highlights Axonics, Bel Fuse and Thermon
by Zacks Equity Research
Axonics, Bel Fuse and Thermon have been highlighted in this Screen of The Week article.
3 Stocks Backed by High Efficiency to Increase Portfolio Returns
by Santanu Roy
Invest in stocks of Axonics (AXNX), Bel Fuse (BELFB) and Thermon (THR) to tap their high-efficiency levels.
Wall Street Analysts Believe Axonics (AXNX) Could Rally 25.1%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.1% in Axonics (AXNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
New Strong Buy Stocks for October 31st
by Zacks Equity Research
SPOT, USAP, COOP, JILL and AXNX have been added to the Zacks Rank #1 (Strong Buy) List on October 31, 2023.
Axonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 260% and 2.41%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
5 Top Stocks Set to Beat Q3 Earnings Estimates on Monday
by Nalak Das
We have narrowed our search to five stocks that are set to declare third-quarter earnings on Monday. These are: XPO, ON, WELL, ACGL, AXNX.
IRhythm Technologies (IRTC) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
IRhythm Technologies (IRTC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axonics Modulation Technologies (AXNX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Axonics (AXNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Thermo Fisher (TMO) in Q3 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) will likely gain from strong Analytical Instrument business performance and latest launches.
Axonics Modulation Technologies (AXNX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of -25% and 7.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 44.12% and 9.85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Axonics Modulation Technologies (AXNX) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 104.35% and 0.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Bilibili (BILI) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Bilibili's (BILI) fourth-quarter 2022 results are likely to reflect strength in mobile gaming revenues. However, increasing channel and marketing expenses are expected to have kept margins under pressure.